Ingen internetforbindelse — viser den gemte version af siden.

Innate Pharma

FREUR
← Til screeneren

Innate Pharma (PA:IPH) — Biotechnology: Biological Products (No Diagnostic Substances). Antal børser, hvor selskabets aktier handles: 3. På denne side — kurs og diagram, udbytte, største aktionærer og historik over antal aktier.

Om virksomheden

Websted
innate-pharma.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Hovedkontor
MARSEILLE, France
Administrerende direktør
Mr. Jonathan E. Dickinson B.Sc., M.B.A.
Ansatte
120
Grundlagt
1999
Udestående aktier
111.7 mio.
Free float
70.45 mio.
Markedsværdi
146.33 mio. EUR
Insidere
17.46%
Institutionelle investorer
10.86%
Branche (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
FR0010331421
Beskrivelse

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.

Børser og tickere

BørsTickerValutaPrisType
PA Euronext ParisIPH primærEUR1.296 -1.07%almindelige aktier
LSE London Stock Exchange0EVI IOBEUR3.0281 +0.00%almindelige aktier
US USA StocksIPHYF OTCUSD1.5092 -8.53%almindelige aktier

Kurs over 3 måneder

PA:IPH · EUR
stigningsdag faldsdag udbyttets ex-dato udbetalingsdatoHold musen over / tryk på en dag — åbnings-, luknings-, højeste og laveste kurs

Udbytte

Ingen udbyttebetalinger fundet (tjekket 08.10.2026). Virksomheden udbetaler sandsynligvis ikke udbytte.

Nyheder denne uge

Ingen nyheder i den sidste uge. Seneste nyheder: 17.09.2026.

annonce

Største ejere

EjerAndelAktierRapportdato
ETF Series Solutions-Ran…0.08%72 6952025-02-28
Lion Point Capital, LP0.07%81 1512026-06-30
Morgan Stanley0.04%43 5242026-06-30
Smartharvest Portfolios,…0.02%23 7502026-06-30
Dimensional ETF Trust-Di…0.02%23 2772026-01-31
Xtx Topco Ltd0.01%15 1302026-06-30
Citadel Advisors Llc0.01%12 4412026-06-30
Jane Street Group, LLC0.01%10 3102026-06-30
Rhumbline Advisers0%4 7192026-06-30
UBS Group AG0%1 3632026-06-30
Farther Finance Advisors…0%212026-06-30
Gamma Investing LLC0%92026-06-30